Loading...
miR-579-3p controls melanoma progression and resistance to target therapy
Therapy of melanoma patients harboring activating mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) oncogene with a combination of BRAF and MEK inhibitors is plagued by the development of drug resistance. Mutational events, as well as adaptive mechanisms, contribute to the devel...
Na minha lista:
| Udgivet i: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
National Academy of Sciences
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5003278/ https://ncbi.nlm.nih.gov/pubmed/27503895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1607753113 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|